{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:44:51Z","timestamp":1792061091700,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101219311"],"award-info":[{"award-number":["101219311"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104821","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:51:32Z","timestamp":1791183092000},"page":"104821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory sandboxes for drug development: from uncertainty to structured evidence generation"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3122-0415","authenticated-orcid":false,"given":"Pedro","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-4862","authenticated-orcid":false,"given":"Maximilian","family":"Otte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-6435","authenticated-orcid":false,"given":"G\u00f6khan","family":"Ertaylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6868-8097","authenticated-orcid":false,"given":"Mika","family":"Naumanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104821_b0005","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaf028","article-title":"The future of AI regulation in drug development: a comparative analysis","volume":"12","author":"Lenarczyk","year":"2025","journal-title":"J Law Biosci"},{"key":"10.1016\/j.drudis.2026.104821_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104821_b0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/d41573-024-00196-z","article-title":"IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases","volume":"24","author":"Krishna","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104821_b0020","article-title":"The status quo of the development of decentralized clinical trials","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104821_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cherd.2025.01.003","article-title":"Continuous manufacturing based paradigm shift in pharmaceuticals production and current regulatory framework","volume":"215","author":"Kashinath","year":"2025","journal-title":"Chem Eng Res Design"},{"key":"10.1016\/j.drudis.2026.104821_b0030","unstructured":"FDA. Digital Health Technologies (DHTs) for Drug Development. www.fda.gov\/science-research\/science-and-research-special-topics\/digital-health-technologies-dhts-drug-development [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0035","unstructured":"FDA. M15 General Principles for Model-Informed Drug Development. 2026;FDA-2024-D-5580. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m15-general-principles-model-informed-drug-development [Accessed 2September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0040","unstructured":"FDA. Real-World Evidence. www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence [Accessed 27 September, 2026],"},{"key":"10.1016\/j.drudis.2026.104821_b0045","doi-asserted-by":"crossref","unstructured":"Buckley RP, et al. Building FinTech ecosystems: regulatory sandboxes, innovation hubs and beyond. SSRN Elec J. Published online 226 September 2019. http:\/\/dx.org\/10.2139\/ssrn.3455872.","DOI":"10.2139\/ssrn.3455872"},{"key":"10.1016\/j.drudis.2026.104821_b0050","doi-asserted-by":"crossref","unstructured":"Zetzsche DA, et al. Regulating a revolution: from regulatory sandboxes to smart regulation. SSRN Elec J. Published online 19 August 2017. https:\/\/doi.org\/10.2139\/ssrn.3018534.","DOI":"10.2139\/ssrn.3018534"},{"key":"10.1016\/j.drudis.2026.104821_b0055","series-title":"Regulatory Sandboxes in Artificial Intelligence","author":"OECD","year":"2023"},{"key":"10.1016\/j.drudis.2026.104821_b0060","first-page":"e35","article-title":"Operationalising AI regulatory sandboxes under the EU AI Act: the triple challenge of capacity, coordination and attractiveness to providers","volume":"1","author":"Ahern","year":"2025","journal-title":"Cambridge Forum AI: Law Governance"},{"key":"10.1016\/j.drudis.2026.104821_b0065","unstructured":"Pharmaceutical Committee. Agenda Item 3b Regulatory Sandboxes. 2026. Accessed April 17, 2026. https:\/\/health.ec.europa.eu\/document\/download\/0d28adc6-c8d2-4ca0-bd4b-c577ff853937_en?filename=mp_20260326_bg856_en.pdf [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0070","first-page":"1","article-title":"Regulation (EU) 2024\/1689 laying down harmonised rules on artificial intelligence","volume":"1689","author":"European Parliament, Council of the European Union","year":"2024","journal-title":"Off J Eur Union"},{"key":"10.1016\/j.drudis.2026.104821_b0075","unstructured":"MHRA. AI Airlock Sandbox Pilot Programme Report. https:\/\/assets.publishing.service.gov.uk\/media\/68ee1fb88427701993d5e02c\/AI_Airlock_Sandbox_Programme_Report_Final.pdf [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0080","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/lapo.12184","article-title":"Fostering regulator\u2013innovator collaboration at the frontline: a case study of the UK\u2019s regulatory sandbox for fintech","volume":"44","author":"Fahy","year":"2022","journal-title":"Law Policy"},{"key":"10.1016\/j.drudis.2026.104821_b0085","unstructured":"EMA. Adaptive Pathways Pilot: Final Report. www.ema.europa.eu\/en\/documents\/report\/final-report-adaptive-pathways-pilot_en.pdf [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1869110","article-title":"From product to knowledge: the life cycle of health technologies 2.0 as a framework for health system improvement","volume":"17","author":"Otte","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104821_b0095","unstructured":"European Commission. Reform of EU Pharmaceutical Legislation. https:\/\/health.ec.europa.eu\/medicinal-products\/reform-eu-pharmaceutical-legislation_en [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0100","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q8(R2): Pharmaceutical Development. https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0105","unstructured":"EMA. Progressing EMA\u2019s Priority Medicines Scheme through New Pilot Features. www.ema.europa.eu\/en\/documents\/report\/progressing-emas-priority-medicines-scheme-through-new-pilot-features_en.pdf [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.rare.2025.100110","article-title":"Regulatory sandboxes: a new frontier for rare disease therapies","volume":"3","author":"Zanello","year":"2025","journal-title":"Rare"},{"key":"10.1016\/j.drudis.2026.104821_b0115","doi-asserted-by":"crossref","unstructured":"Macrae C, Ansell CK. Generative Spaces: Collaboration, Learning and Innovation in a Regulatory Sandbox. SSRN Elec J. Published online 13 May 2024. https:\/\/doi.org\/10.2139\/ssrn.4825907.","DOI":"10.2139\/ssrn.4825907"},{"key":"10.1016\/j.drudis.2026.104821_b0120","unstructured":"FDA. The Software Precertification (Pre-Cert) Pilot Program. 2022. www.fda.gov\/media\/161815\/download [Accessed 27 September, 2026]."},{"key":"10.1016\/j.drudis.2026.104821_b0130","series-title":"Inside the Regulatory Sandbox: Effects on Fintech Funding","author":"Cornelli","year":"2020"},{"key":"10.1016\/j.drudis.2026.104821_b0135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/isj.70004","article-title":"FinTechs playing in the regulatory sandbox\u2014the effect of interacting signals on funding","volume":"36","author":"Kindermann","year":"2025","journal-title":"Inf Syst J"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:53:07Z","timestamp":1792057987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002266"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104821","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory sandboxes for drug development: from uncertainty to structured evidence generation","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104821"}}